RT Journal Article
SR Electronic
T1 Etanercept-induced myositis: do we have to stop it? A surprising outcome
JF BMJ Case Reports
FD BMJ Publishing Group Ltd
SP bcr2015213577
DO 10.1136/bcr-2015-213577
VO 2016
A1 Hassan Tariq
A1 Bibi Ayesha
A1 Karen Weidenheim
A1 Giovanni Franchin
YR 2016
UL http://casereports.bmj.com/content/2016/bcr-2015-213577.abstract
AB We discuss a case of a 47-year-old man who presented with progressive proximal muscle weakness of the upper and lower extremities and unstable gait. He had been on etanercept for 6 months for severe psoriasis and psoriatic arthritis with good control of his disease. Serum creatine kinase (CK) level was found to be 5666 U/L and muscle biopsy showed a marked inflammatory myopathic process likely secondary to etanercept. He was started on high-dose steroids and advised to discontinue etanercept. Despite our recommendation, he never stopped using etanercept due to fear of a psoriasis flare. Three months later, he had significant improvement of clinical symptoms, normalised serum CK levels and discontinued prednisone.